Massa Michela, Franchelli Simonetta, Panizza Renzo, Massa Tiberio
1Plastic and Reconstructive Surgery, SS. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy;
2Plastic and Reconstructive Surgery, IRCCS AOU San Martino-IST, National Institute of Cancer Research, L.go Rosanna Benzi 10, 16132, Genoa, Italy;
Chin J Cancer Res. 2016 Apr;28(2):146-9. doi: 10.21147/j.issn.1000-9604.2016.02.01.
After the results obtained in the two randomized clinical trial, the ELIOT trial and the TARGIT-A trial, a heated debate is going on concerning the question of applying intraoperative radiotherapy (IORT) instead of postoperative whole breast irradiation (WBI) after breast conservative treatment. Currently, many centers are applying the IORT following the strict selection criteria dictated by the working groups American Society for Radiation Oncology (ASTRO) and Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) and monitoring the oncological outcome together with radiation toxicity on breast tissue. The clinical experience of the Geneva University Hospital regarding the use of the Intrabeam system is evaluated and compared with current evidences.
在两项随机临床试验(ELIOT试验和TARGIT-A试验)得出结果之后,关于在保乳治疗后应用术中放疗(IORT)而非术后全乳照射(WBI)的问题,正在进行一场激烈的辩论。目前,许多中心正在按照美国放射肿瘤学会(ASTRO)和欧洲近距离治疗协会-欧洲治疗放射学和肿瘤学协会(GEC-ESTRO)工作组规定的严格选择标准应用IORT,并同时监测肿瘤学结局以及乳腺组织的放射毒性。对日内瓦大学医院使用Intrabeam系统的临床经验进行了评估,并与当前证据进行了比较。